
|Articles|July 21, 2008
NovaBay anounces details of dermatology program
Emeryville, Calif. - NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology.
Advertisement
Emeryville, Calif.
- NovaBay Parmaceuticals announces it has successfully developed several formulations of Agonocide compounds for use in dermatology, according to iStockAnalysis.com.
One formulations, AgaDerm, delivers an Aganocide compound effectively when applied on the surface of the skin, and furthered penetration into hair follicles to treat fungal infections.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Next-Generation IL-4Rα Targeting and Potential Dermatologic Implications
2
Alpha Tau Submits First PMA Module to FDA for Novel cSCC Treatment, Alpha DaRT
3
Comparative Analysis Positions Zasocitinib Among Next-Generation TYK2 Inhibitors
4
Journal Digest: January 14, 2026
5


















